Xiuzhi Zhang

Xiuzhi Zhang

Auto-generated profile, based on publicly available information

Xiuzhi Zhang

Dalian University Orthopaedic Medical Research Center Dalian, Liaoning 116001

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
XZXiuzhi Zhang
Xiuzhi Zhang
TLTianhao Liu
Tianhao Liu
CRChunxiao Ran
Chunxiao Ran
WWWeidan Wang
Weidan Wang
FPFengyuan Piao
Fengyuan Piao
DZDeWei Zhao
DeWei Zhao
Osteoarthritis (OA) is a degenerative joint disease caused by chronic inflammation that damages articular cartilage. At present, the treatment of OA includes drug therapy to relieve symptoms and joint replacement therapy for advanced OA. However, these palliatives cannot truly block the progression of the disease from the immunological pathogenesis of OA. In recent years, bone marrow mesenchymal stem cell (BMSC) transplantation has shown great potential in tissue engineering repair. In addition, many studies have shown that BMSC paracrine signals play an important role in the treatment of OA through immune regulation and suppressing inflammation. At present, the mechanism of inflammation-induced OA and the use of BMSC transplantation in joint repair have been reviewed, but the mechanism and significance of BMSC paracrine signals in the treatment of OA have not been fully reviewed. Therefore, this article focused on the latest research progress on the paracrine effects of BMSCs in the treatment of OA and the related mechanisms by which BMSCs secrete cytokines to inhibit the inflammatory response, regulate immune balance, and promote cell proliferation and differentiation. In addition, the application potential of BMSC-Exos as a new type of cell-free therapy for OA is described. This review aimed to provide systematic theoretical support for the clinical application of BMSC transplantation in the treatment of OA.

2 January 2024 in Regenerative Biomaterials
Verified
Journal Article
Open access
PDF file
DZDeWei Zhao
DeWei Zhao
Liang ChengLiang Cheng
Liang Cheng
FLFaqiang Lu
Faqiang Lu
XZXiuzhi Zhang
Xiuzhi Zhang
JYJiawei Ying
Jiawei Ying
JLJunlei Li
Junlei Li
The joint prosthesis plays a vital role in the outcome of total hip arthroplasty. The key factors that determine the performance of joint prostheses are the materials used and the structural design of the prosthesis. This study aimed to fabricate a porous tantalum (Ta) hip prosthesis using selective laser melting (SLM) technology. The feasibility of SLM Ta use in hip prosthesis was verified by studying its chemical composition, metallographic structure and mechanical properties. In vitro experiments proved that SLM Ta exhibited better biological activities in promoting osteogenesis and inhibiting inflammation than SLM Ti6Al4V. Then, the topological optimization design of the femoral stem of the SLM Ta hip prosthesis was carried out by finite element simulation, and the fatigue performance of the optimized prosthesis was tested to verify the biomechanical safety of the prosthesis. A porous Ta acetabulum cup was also designed and fabricated using SLM. Its mechanical properties were then studied. Finally, clinical trials were conducted to verify the clinical efficacy of the SLM Ta hip prosthesis. The porous structure could reduce the weight of the prosthesis and stress shielding and avoid bone resorption around the prosthesis. In addition, anti-infection drugs can also be loaded into the pores for infection treatment. The acetabular cup can be custom-designed based on the severity of bone loss on the acetabular side, and the integrated acetabular cup can repair the acetabular bone defect while achieving the function of the acetabular cup.

12 February 2021 in Medicine
Verified
Journal Article
Open access
YLYang Liu
Yang Liu
LKLin Kang
Lin Kang
HHHan Hao
Han Hao
XZXiuzhi Zhang
Xiuzhi Zhang
GZGuona Zheng
Guona Zheng
HZHuanfen Zhao
Huanfen Zhao
Rationale: Double primary lung cancer (DPLC) is a relatively rare type of lung cancers. According to whether the diagnosis interval between lesions is more than 6 months, it can be divided into synchronous DPLC (sDPLC) and metachronous DPLC (mDPLC). Here, we describe a case of sDPLC in which one of the components is a rare colloid adenocarcinoma (CA). Patient concerns: A 69-year-old male was admitted to the hospital due to chest distress and shortness of breath for 1 year, getting worse in the last 15 days. Diagnosis: Both HE staining and IHC supported the diagnosis of CA in the right lower lobe and moderately differentiated squamous cell carcinoma in the right upper lobe. Interventions: The patient was treated with 3 cycles of adjuvant chemotherapy with pemetrexed and lobaplatin after the right upper lobectomy, wedge resection of the right lower lobe and lymph node dissection under video-assisted thoracoscope. Outcomes: Our plan was to follow him up with general physical examination, chest-abdomen CT and serum tumor markers every 6 months for 2 years. The patient was still alive until the last follow-up in November 2020. Lessons: CA of the lung is a rare primary lung adenocarcinoma. The diagnosis should be based on the patient's clinical characteristics, imaging examination and pathological characteristics, and also need to be differentiated from other mucinous adenocarcinomas. Interestingly, our patient developed not only a CA in the right lower lobe, but also a moderately differentiated squamous cell carcinoma in the right upper lobe.

22 January 2026 in Regenerative Biomaterials
Verified
Journal Article
Open access
PDF file
QGQiang Guo
Qiang Guo
CRChunxiao Ran
Chunxiao Ran
ZWZixin Wang
Zixin Wang
XZXiuzhi Zhang
Xiuzhi Zhang
YYYiqun Yao
Yiqun Yao
DZDeWei Zhao
DeWei Zhao
Advances in orthopedic biomaterials have significantly improved the bone regeneration domain; however, postoperative bone defect repair after bone tumor resection—particularly for osteosarcoma, a common primary malignant bone tumor in children and adolescents—remains a critical exception. Osteosarcoma’s aggressiveness, early metastatic propensity, and immunosuppressive tumor microenvironment (OS-TME) limit conventional therapies, yielding poor prognosis in recurrence or metastasis cases. Although traditional tissue engineering promotes bone regeneration, it inadvertently sustains tumor growth, recurrence, and metastasis via cytokines such as TGF-β1, VEGF, and BMP-2. Mesenchymal stem cells and induced pluripotent stem cells (iPSCs) worsen this by inducing M2 macrophage polarization, creating a tumor-supportive immune niche. Our prior research on biodegradable magnesium for bone repair showed Mg2+ enhances osteogenesis by activating PI3K/AKT via the TRPM7 channel; yet, TRPM7 as an oncogene links to tumor invasion and metastasis, posing risks for magnesium-based scaffolds in osteosarcoma defect repair. Thus, traditional tissue engineering’s three core elements (seed cells, scaffolds, cytokines) fail to meet dual needs of anti-tumor efficacy and bone regeneration in post-tumor defects. Recent tumor immunology breakthroughs have driven immuno-tissue engineering’s rise, offering new opportunities for osteosarcoma defect repair. Still, limited understanding of OS-TME mechanisms hinders clinical translation. This review delineates OS-TME's immune landscape, covering immune cells (e.g., TAMs, Tregs, MDSCs), checkpoints (e.g., PD-1, CTLA-4, CD47), and immunotherapies, and explores their tissue engineering integration through sequential release, spatiotemporal targeting, immune modulation, and multimodal analyses (e.g., single-cell RNA sequencing, spatial transcriptomics) to optimize material design. We propose immune modulation as a novel “fourth element” in tissue engineering, beyond the conventional seed cells, scaffolds, and cytokines framework. This exposition lays a theoretical foundation for osteosarcoma immuno-tissue engineering repair and inspires innovative biomaterial solutions.